A MARCKS Effector Domain-Derived Cytotoxic Peptide Induces Acute Tumor Cell Death

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Peptide drugs offer targeted cancer therapy with fewer side effects.
• The MARCKS effector domain (ED) peptide shows potential for inhibiting cancer cell function and inducing death.

Purpose of the Study:

• To investigate the cytotoxic efficacy of a modified MARCKS ED peptide (4A-TAT).
• To evaluate the peptide's mechanism of action and its potential for cancer treatment.

Main Methods:

• Synthesized a non-phosphorylating MARCKS ED peptide with four serine-to-alanine mutations (4A) and fused it with a transactivator of transcription (TAT) sequence (4A-TAT).
• Assessed the cytotoxicity of 4A-TAT against various tumor cell lines and normal human B cells.
• Investigated the mechanism of cell death induced by 4A-TAT, including plasma membrane integrity, calcium homeostasis, and organelle function.

Main Results:

• The 4A-TAT peptide exhibited rapid and potent cytotoxicity against diverse tumor cell lines.
• 4A-TAT demonstrated low toxicity towards normal human B cells.
• Mechanistically, 4A-TAT induces cell death by rapidly disrupting plasma membrane integrity, leading to calcium dyshomeostasis and organelle dysfunction, resulting in non-apoptotic cell death.

Conclusions:

• The 4A-TAT peptide is a highly effective cytotoxic agent against tumor cells in vitro and in vivo.
• The study highlights the critical role of the ED4A component and the TAT sequence in the peptide's potent cytotoxic activity.
• 4A-TAT represents a promising candidate for novel cancer therapeutic strategies.